

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – October 10, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. September 12, 2012 DUR Minutes – Vote
 - B. September 13, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review Response for April 2012
 - B. Medication Coverage Activity for September 2012
 - C. Pharmacy Help Desk Activity for September 2012
 - D. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Cialis[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Neupro[®] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Bladder Control Medications and 30 Day Notice to Prior Authorize Myrbetriq™ – See Appendix E.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Myrbetriq™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Antidepressants and 30 Day Notice to Prior Authorize Forfivo XL™ and Fluoxetine 60mg – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Forfivo XL™ Product Details

Items to be presented by Dr. Sipols, Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Alzheimer's Medications® – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

10. **30 Day notice to Prior Authorize Miscellaneous Butalbital Products – See Appendix H.**
 - A. Overview
 - B. Cost Comparison
 - C. COP Recommendations
 - D. Product Information

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
 - A. Annual Reviews
 - B. New Product Reviews
 - C. Utilization Review of COPD Medications

13. **Adjournment**